AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10229430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 8709356 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pediatric donor kidneys
Number of subjects: 60
Study 8709356 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pediatric donor kidneys with cyclosporine
Number of subjects: 60
Study 8709356 — intervention group
Group type: COMPARATOR
Intervention: Adult donor kidneys
Number of subjects: 60
Study 2010061 — intervention group
Group type: COMPARATOR
Intervention: Choline supplementation (500 mg/day)
Number of subjects: 0
Study 2010061 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-deficient diet
Number of subjects: 0
Study 7099731 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (dosage adjusted based on nervous system classification)
Number of subjects: 0
Study 7099731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31936720 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut consumption (Juglans regia L.) for 4 weeks
Number of subjects: 18
Study 31823292 — intervention group
Group type: EXPERIMENTAL
Intervention: Early free‐spins
Number of subjects: 188
Study 31823292 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study 31823292 — intervention group
Group type: EXPERIMENTAL
Intervention: Late free‐spins
Number of subjects: 188
Study 29479695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost data presented using actual dollar amounts
Number of subjects: 420
Study 29479695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost data presented using the word 'affordable' for low-cost hospitals
Number of subjects: 420
Study 29479695 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission performance shown using word icons
Number of subjects: 420
Study 29479695 — intervention group
Group type: COMPARATOR
Intervention: Hospital Compare spending ratio
Number of subjects: 420
Study 26850418 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 100
Study 26850418 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 100
Study 24746755 — intervention group
Group type: EXPERIMENTAL
Intervention: Introitus group (held for 2 min at the level of the vagina)
Number of subjects: 546
Study 24746755 — intervention group
Group type: COMPARATOR
Intervention: Abdomen group (held on the mother's abdomen or chest)
Number of subjects: 546
Study 22183214 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg synthetic conjugated estrogens-B
Number of subjects: 157
Study 22183214 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg synthetic conjugated estrogens-B
Number of subjects: 157
Study 22183214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 20815158 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 225
Study 20815158 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (Propranolol, Atenolol, Pindolol)
Number of subjects: 225
Study 20815158 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 225
Study 20815158 — intervention group
Group type: COMPARATOR
Intervention: Control group (Healthy volunteers)
Number of subjects: 225
Study 17513033 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (one short unidirectional FRC prepregs placed on the main prepregs at 90 degrees)
Number of subjects: 48
Study 17513033 — intervention group
Group type: COMPARATOR
Intervention: Group A (control group: two prepregs of unidirectional glass FRC)
Number of subjects: 48
Study 17513033 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (two prepregs in pontic portion covered with one layer of multidirectional fiber veil FRC)
Number of subjects: 48
Study 17513033 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (FRC prepregs covered in pontic portion with four short unidirectional FRC pieces)
Number of subjects: 48
Study 15814542 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulphone (PS) dialysis membrane
Number of subjects: 8
Study 15814542 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerated cellulose (RC) dialysis membrane
Number of subjects: 8
Study 15814542 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PS and RC membranes
Number of subjects: 8
Study 12108501 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 0
Study 12108501 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 0
Study 9453014 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (BBL)
Number of subjects: 13
Study 9453014 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB)
Number of subjects: 13
Study 9453014 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitor (CEI)
Number of subjects: 13
Study 9453014 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker (ABL)
Number of subjects: 13
Study 9453014 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 13
Study 9453014 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (MOX)
Number of subjects: 13
Study 9453014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study 7615046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone, Etoposide, and Ara-C (MEA)
Number of subjects: 86
Study 7615046 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-DNA, Ara-C, Thioguanine, Vincristine, and Prednisolone (POCAL-DNA)
Number of subjects: 86
Study 2565265 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Number of subjects: 81
Study 2565265 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine
Number of subjects: 81
Study 2565265 — intervention group
Group type: COMPARATOR
Intervention: 10 mg astemizole
Number of subjects: 81
Study 1175125 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone)
Number of subjects: 108
Study 1175125 — intervention group
Group type: COMPARATOR
Intervention: HN2 (nitrogen mustard)
Number of subjects: 108
Study 1175125 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 108
Study 1175125 — intervention group
Group type: COMPARATOR
Intervention: HN2
Number of subjects: 108
Study 31619335 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (bolus dose, 5 μg kg‐1; CRI, 3.5 μg kg‐1 hour‐1)
Number of subjects: 50
Study 31619335 — intervention group
Group type: COMPARATOR
Intervention: Detomidine (bolus dose, 10 μg kg‐1; CRI, 6 μg kg‐1 hour‐1)
Number of subjects: 50
Study 31554370 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam (PIP/TZO) 320 mg/kg/day divided every 8 hours
Number of subjects: 70
Study 31554370 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 100 mg/kg/day divided every 8 hours plus Amikacin 15 mg/kg/day once daily
Number of subjects: 70
Study 27522630 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125-guided therapy (CA125 strategy)
Number of subjects: 380
Study 27522630 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 380
Study 24492988 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 164
Study 24492988 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 164
Study 22717835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 80
Study 22717835 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 80
Study 20861586 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg NWP06 (extended-release methylphenidate)
Number of subjects: 30
Study 20861586 — intervention group
Group type: COMPARATOR
Intervention: 30 mg immediate-release methylphenidate (IR MPH)
Number of subjects: 30
Study 20861586 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg NWP06
Number of subjects: 30
Study 20861586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NWP06 and IR MPH
Number of subjects: 30
Study 18445142 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitizers
Number of subjects: 74
Study 18445142 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise programme
Number of subjects: 74
Study 16422874 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand tadalafil (20 mg)
Number of subjects: 145
Study 16422874 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tadalafil (10 mg)
Number of subjects: 145
Study 12660257 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 48
Study 12660257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation for IVF
Number of subjects: 48
Study 12660257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraception
Number of subjects: 48
Study 12660257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrogesterone for endometrial luteal phase defect
Number of subjects: 48
Study 12660257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (two different regimens)
Number of subjects: 48
Study 12660257 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy fertile women)
Number of subjects: 48
Study 10618463 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic imipramine treatment
Number of subjects: 64
Study 1862965 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent endotracheal anesthesia with controlled lung ventilation and postoperative intramuscular analgesia with non-narcotic and narcotic analgesics (Group I)
Number of subjects: 60
Study 1862965 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia with 2.5% trimecaine solution combined with adrenaline and small morphine doses at the upper thoracic segment level, with postoperative analgesia for 18 hours (Group II)
Number of subjects: 60
Study 6412263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (100, 200, 400 mg)
Number of subjects: 0
Study 6412263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (15, 30 mg)
Number of subjects: 0
Study 6412263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30720444 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% cadexomer iodine ointment plus standard care
Number of subjects: 124
Study 30720444 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% cadexomer iodine powder plus standard care
Number of subjects: 124
Study 30720444 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 124
Study 30080085 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT + EUC
Number of subjects: 36
Study 30080085 — intervention group
Group type: COMPARATOR
Intervention: EUC
Number of subjects: 36
Study 26613985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose gel
Number of subjects: 184
Study 26613985 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 184
Study 24642406 — intervention group
Group type: EXPERIMENTAL
Intervention: iA-CPR
Number of subjects: 4753
Study 24642406 — intervention group
Group type: COMPARATOR
Intervention: M-CPR
Number of subjects: 4753
Study 22042967 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 22042967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20702523 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 12 months
Number of subjects: 46
Study 18163919 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (LDD) 20 mg twice a day for 10 weeks
Number of subjects: 22
Study 18163919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16339329 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) including 3 months of low intensity exercise and 3 months of progressive resistance training (PRT)
Number of subjects: 91
Study 16339329 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL) group performing a low intensity home exercise program
Number of subjects: 91
Study 12667328 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital colposcope (SLC‐2000)
Number of subjects: 196
Study 12667328 — intervention group
Group type: COMPARATOR
Intervention: Optical colposcope
Number of subjects: 196
Study 9649964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (10, 30, 56, and 100 mg)
Number of subjects: 9
Study 9649964 — intervention group
Group type: EXPERIMENTAL
Intervention: LY297802 (0.1, 0.3, 0.56, and 1 mg)
Number of subjects: 9
Study 9649964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7675376 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 25 micrograms every 2 hours
Number of subjects: 0
Study 7675376 — intervention group
Group type: COMPARATOR
Intervention: Intracervical PGE2 gel 0.5 mg administered at 6-hour intervals
Number of subjects: 0
Study 2044014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate 60 mg once daily
Number of subjects: 0
Study 2044014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 30 mg qid
Number of subjects: 0
Study 7360088 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 22
Study 7360088 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran
Number of subjects: 22
Study 7360088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31015374 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe sleep intervention videos
Number of subjects: 1263
Study 28474780 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC (80 mcg daily subcutaneous injections for 18 months)
Number of subjects: 1645
Study 28474780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1645
Study 26940110 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based weight management and healthy lifestyle programme (6-month duration)
Number of subjects: 120
Study 26940110 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 24576893 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of 50% glucose only
Number of subjects: 10
Study 24576893 — intervention group
Group type: COMPARATOR
Intervention: 10 units of insulin with 100 ml of 50% glucose (50 g)
Number of subjects: 10
Study 22984785 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening using PSA testing
Number of subjects: 666
Study 22984785 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening in Sweden
Number of subjects: 666
Study 19916207 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 174
Study 19916207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 17523386 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergovit 6-grass pollen preparation
Number of subjects: 154
Study 14660217 — intervention group
Group type: EXPERIMENTAL
Intervention: Power grip
Number of subjects: 20
Study 14660217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pinch
Number of subjects: 20
Study 14660217 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulp pinch
Number of subjects: 20
Study 14660217 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal grip force exertion
Number of subjects: 20
Study 11163780 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 11163780 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 0
Study 9849475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CP) every 28 days for six courses
Number of subjects: 176
Study 9849475 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 every 28 days for six courses
Number of subjects: 176
Study 9849475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CP)
Number of subjects: 176
Study 9849475 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2
Number of subjects: 176
Study 9849475 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-containing chemotherapy
Number of subjects: 176
Study 9849475 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-free regimens
Number of subjects: 176
Study 9849475 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum second-line therapy
Number of subjects: 176
Study 8300993 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a combination of food models and life-sized food photographs (experimental group, n = 18)
Number of subjects: 44
Study 8300993 — intervention group
Group type: COMPARATOR
Intervention: Training with food models (control group, n = 26)
Number of subjects: 44
Study 8300993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training techniques (experimental and control)
Number of subjects: 44
Study 2230213 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical all‐trans retinoic acid (0.05%) applied to the forearms for 6 months
Number of subjects: 27
Study 2230213 — intervention group
Group type: COMPARATOR
Intervention: Excipient alone (untreated forearm)
Number of subjects: 27
Study 2230213 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical all‐trans retinoic acid (0.05%)
Number of subjects: 27
Study 116285 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 30
Study 116285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 30
Study 30369087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock recruitment protocol
Number of subjects: 45
Study 30369087 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns raised during mock recruitment
Number of subjects: 45
Study 28975305 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker-led multicomponent intervention (health coaching, home BP monitoring, BP audit and feedback, physician intervention, text-messaging intervention) over 18 months
Number of subjects: 1432
Study 28975305 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1432
Study 25972260 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 81
Study 25972260 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab
Number of subjects: 81
Study 25972260 — intervention group
Group type: COMPARATOR
Intervention: ranibizumab plus laser
Number of subjects: 81
Study 25972260 — intervention group
Group type: COMPARATOR
Intervention: ranibizumab
Number of subjects: 81
Study 23343138 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Telemonitoring (HBPT)
Number of subjects: 252
Study 23343138 — intervention group
Group type: COMPARATOR
Intervention: Conventional Management (CM)
Number of subjects: 252
Study 21896561 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin iv 400 mg once daily followed by oral 400 mg once daily
Number of subjects: 813
Study 21896561 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (TZP) iv 4.0/0.5 g thrice daily followed by oral amoxicillin/clavulanate (AMC) 875/125 mg twice daily
Number of subjects: 813
Study 21896561 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin iv/oral
Number of subjects: 813
Study 21896561 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (TZP) iv followed by oral amoxicillin/clavulanate (AMC)
Number of subjects: 813
Study 19969174 — intervention group
Group type: EXPERIMENTAL
Intervention: Retraining with the Dynavision apparatus for 18 sessions
Number of subjects: 26
Study 19969174 — intervention group
Group type: COMPARATOR
Intervention: No intervention (waitlist)
Number of subjects: 26
Study 17225260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening and risk counseling
Number of subjects: 592
Study 17225260 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 592
Study 17225260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening with abnormal test results
Number of subjects: 592
Study 15590951 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary surgical cytoreduction plus chemotherapy
Number of subjects: 550
Study 15590951 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 550
Study 11513442 — intervention group
Group type: EXPERIMENTAL
Intervention: Bachmann's bundle (BB) pacing
Number of subjects: 120
Study 11513442 — intervention group
Group type: COMPARATOR
Intervention: Right atrial appendage (RAA) pacing
Number of subjects: 120
Study 9587124 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adjuvant radiation therapy (RT)
Number of subjects: 53
Study 9587124 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 53
Study 9587124 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy (RT)
Number of subjects: 53
Study 7834258 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 58
Study 7834258 — intervention group
Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 58
Study 7834258 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Propofol and Methohexital)
Number of subjects: 58
Study 2499234 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 6
Study 2499234 — intervention group
Group type: COMPARATOR
Intervention: 21% O2
Number of subjects: 6
Study 2499234 — intervention group
Group type: COMPARATOR
Intervention: 40% O2
Number of subjects: 6
Study 806293 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate
Number of subjects: 11
Study 806293 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17 valerate
Number of subjects: 11
Study 806293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs combined (disodium cromoglycate and betamethasone 17 valerate)
Number of subjects: 11
Study 806293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31888372 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic alignment (KA)
Number of subjects: 125
Study 31888372 — intervention group
Group type: COMPARATOR
Intervention: Mechanical alignment (MA)
Number of subjects: 125
Study 31268555 — intervention group
Group type: EXPERIMENTAL
Intervention: Staccato alprazolam 0.5 mg
Number of subjects: 5
Study 31268555 — intervention group
Group type: EXPERIMENTAL
Intervention: Staccato alprazolam 1.0 mg
Number of subjects: 5